MERCK & CO: Mulls Options on Revoked Fosamax Patent in Europe
Merck & Co. Inc. is considering its options regarding the Company’s European patent covering once-weekly dosing of Fosamax.
In September 2004, the Company appealed a decision of the Opposition Division of…